Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
J Am Acad Dermatol
; 70(1): 60-9, 2014 Jan.
Article
em En
| MEDLINE
| ID: mdl-24189279
Palavras-chave
AE; BCC; BCNS; ECOG; Eastern Cooperative Oncology Group; FDA; Hedgehog pathway inhibitor; ORR; RECIST; Response Evaluation Criteria in Solid Tumors; SMO; Smoothened; TEAE; US Food and Drug Administration; adverse event; basal cell carcinoma; basal cell nevus syndrome; expanded access; locally advanced; metastatic; objective response rate; treatment-emergent adverse event; vismodegib
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Piridinas
/
Neoplasias Cutâneas
/
Neoplasias Ósseas
/
Carcinoma Basocelular
/
Anilidas
/
Antineoplásicos
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Am Acad Dermatol
Ano de publicação:
2014
Tipo de documento:
Article